Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Why Is Everyone Ignoring Gilead Stock's High Cash Yield?

Acquisition Guidance lowered AI-generated analysis

πŸ“ˆ Gilead generated free cash flow equal to 7.1% of its market value over the last twelve months, significantly outpacing the S&P 500 median yield of 4.5%.

πŸ’Š The HIV drug Biktarvy drove $14.3 billion of Gilead's $29.4 billion fiscal 2025 revenue, contributing to a robust 38.5% operating margin.

πŸ“‰ Sales for the non-HIV drug Veklury were lowered to approximately $300 million for the full year, down from an earlier forecast of $600 million.

πŸ”¬ Cell therapy sales declined 14% year-over-year in the most recent quarter due to increased market competition.

πŸ’° Gilead spent $11.2 billion on outside research programs and acquisitions during the quarter to diversify its portfolio beyond HIV treatments.

πŸ“‰ The company reported a net loss of $3.2 billion over the last twelve months, resulting in no meaningful P/E ratio for the stock.

πŸš€ Management raised its full-year 2026 HIV sales growth forecast to a range between 9% and 10%, up from the previous 8% guidance.

βš–οΈ Gilead's operating profit covers its interest bill 11.7 times over, indicating strong ability to service its net debt of 12.6% of market value.

Bullish Signals
  • Gilead generated free cash flow equal to 7.1% of its market value over the last twelve months, significantly exceeding the S&P 500 median yield of 4.5%.
  • The company achieved a high operating margin of 38.5%, driven by the blockbuster HIV drug Biktarvy which generated $14.3 billion in revenue.
  • Free cash flow expanded to $12.9 billion over the last twelve months, up from $9.4 billion a year earlier, demonstrating growing capital generation.
  • Management raised its forecast for 2026 HIV sales growth to a range between 9% and 10%, indicating confidence in the expansion of its largest business segment.
  • Gilead comfortably covers its interest obligations with an operating profit coverage ratio of 11.7x, ensuring debt service is not a constraint on cash returns.
Risk Factors
  • The market prices in significant risks due to the company's heavy reliance on HIV treatments and declining sales in non-HIV segments.
  • Sales for the non-HIV drug Veklury were lowered to approximately $300 million for the full year, down from a previous forecast of $600 million.
  • Cell therapy revenue fell 14% from a year earlier during the quarter due to market competition pressures.
  • Gilead reported a net loss of $3.2 billion over the last twelve months due to acquisition charges, resulting in no meaningful P/E ratio for valuation.
  • The company faces the challenge of proving that cash generation will continue to grow despite the contraction in Veklury and cell therapy sales.
Full Analysis
Gilead Sciences (GILD) demonstrates strong cash generation capabilities, producing free cash flow equal to 7.1% of its market value over the last twelve months, significantly higher than the S&P 500 median of 4.5%. The company's operating margin stands at 38.5%, driven largely by its blockbuster HIV drug Biktarvy, which accounted for $14.3 billion of the $29.4 billion total revenue in fiscal 2025. Despite carrying net debt equal to 12.6% of market value, Gilead comfortably covers interest obligations with an operating profit coverage ratio of 11.7x. However, investors are pricing in risks related to the company's heavy reliance on HIV treatments and declining performance in non-HIV segments. Specifically, sales for Veklury were lowered to approximately $300 million for the full year, and cell therapy revenue fell 14% due to market competition. To mitigate this concentration risk, Gilead spent $11.2 billion on research programs and acquisitions during the quarter, though these expenses contributed to a net loss of $3.2 billion over the last twelve months. Looking ahead, management has raised its forecast for HIV sales growth to 9-10% for fiscal 2026, signaling confidence in its core business expansion despite the contraction elsewhere. The stock currently lacks a meaningful P/E ratio due to the net loss, but the high cash yield suggests the market may be undervaluing the company's durable cash-generating assets if HIV growth targets are met and non-HIV declines stabilize.